Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The hazard ratio (HR) for HF among diabetic individuals was 2.70 (95% confidence interval [CI], 2.49 − 2.93) when compared to non-diabetic participants.Characteristics of the study samplesSample 1 (whole sample: DAN-MONICA, FINRISK, Moli-sani, SHHEC, Northern Sweden MONICA)Sample 2 (sample with biomarker data available: FINRISK, Moli-sani, SHHEC, Northern Sweden MONICA)OverallDiabetesNo diabetesMissing, n (%)OverallDiabetesNo diabetesMissing, n (%)Demographics n94,011 (100)3,834 (100)90,177 (100)55,271 (100)2,472 (100)52,799 (100)Cohort DAN-MONICA7,526 (8.0)178 (4.6)7,348 (8.1) FINRISK36,907 (39.3)1,526 (39.8)35,381 (39.2)7,852 (14.2)397 (16.1)7,455 (14.1) Moli-sani23,249 (24.7)1,468 (38.3)21,781 (24.2)23,198 (42.0)1,465 (59.3)21,733 (41.2) SHHEC15,959 (17.0)276 (7.2)15,683 (17.4)14,190 (25.7)239 (9.7)13,951 (26.4) Northern SwedenMONICA10,370 (11.0)386 (10.1)9,984 (11.1)10,031 (18.2)371 (15.0)9,660 (18.3)Women48,320 (51.4)1,771 (46.2)46,549 (51.6)28,307 (51.2)1,066 (43.1)27,241 (51.6)Age, years48.65 (12.5)57.65 (11.7)48.27 (12.4)51.08 (12.2)60.45 (11.4)50.64 (12.1)Medication Antihypertensive treatment13,522 (14.4)1,632 (42.6)11,890 (13.1)3,284 (3.5)9,833 (17.8)1,199 (48.5)8,634 (16.4)412 (0.7) Lipid lowering treatment3,099 (3.3)579 (15.1)2,520 (2.8)30,281 (32.2)2,465 (4.5)479 (19.4)1,986 (3.8)15,704 (28.4) Diabetes treatment Oral1,427 (37.2)810 (21.1)1,148 (46.4)518 (21.0) Insulin607 (15.8)810 (21.1)388 (15.7)518 (21.0) Diet990 (25.8)810 (21.1)418 (16.9)518 (21.0)Risk factors Alcohol use, g/d10.82 (18.0)10.60 (18.7)10.83 (18.0)2,343 (2.5)12.13 (19.4)12.41 (20.0)12.12 (19.4)1,937 (3.5) BMI, kg/m226.17 (4.6)29.16 (5.5)26.05 (4.5)806 (0.9)26.61 (4.7)29.56 (5.5)26.47 (4.6)97 (0.2) Smokers29,914 (31.8)862 (22.5)29,052 (32.2)161 (0.2)16,140 (29.2)475 (19.2)15,665 (29.7)42 (0.1) Systolic BP, mmHg135.23 (20.6)145.80 (22.0)134.79 (20.4)761 (0.8)135.66 (20.8)147.42 (22.0)135.11 (20.6)15 (0.0) Baseline MI2,194 (2.3)303 (7.9)1,891 (2.1)289 (0.3)1,450 (2.6)215 (8.7)1,235 (2.3)228 (0.4) Baseline AF560 (0.6)51 (1.3)501 (0.6)6,328 (6.8)423 (0.8)51 (2.1)372 (0.7)6,371 (11.5)Biomarkers HDL, mmol/l1.4 (1.2 − 1.7)1.3 (1.1 − 1.5)1.4 (1.2 − 1.7)2996 (5.4) LDL, mmol/l3.0 (2.4 − 3.8)2.9 (2.3 − 3.5)3.0 (2.4 − 3.8)3019 (5.4) Triglycerides, mmol/l1.2 (0.9 − 1.7)1.4 (1.0 − 1.9)1.20 (0.9 − 1.6)2956 (5.3) Insulin, pmol/l6.6 (4.5 − 10.0)9.6 (6.2 − 15.4)6.5 (4.4 − 9.8)1894 (3.4) Glucose, mmol/l4.9 (4.5 − 5.5)7.3 (5.8 − 9.5)4.9 (4.5 − 5.4)3,466 (6.2) Creatinine, μmol/l70.7 (61.9 − 79.6)72.5 (63.6 − 85.7)70.7 (61.9 − 79.6)1120 (2.0) hs-CRP, mg/l1.4 (0.6 − 2.9)2.0 (0.9 − 4.3)1.3 (0.6 − 2.8)1109 (2.0) nT-proBNP, pg/ml48.3 (25.5 − 90.2)67.1 (32.5 − 143.3)47.7 (25.3 − 88.1)6678 (12.1) hs-TnI, pg/ml2.5 (1.4 − 4.3)3.2 (2.0 − 5.5)2.4 (1.4 − 4.2)2643 (4.8) Vitamin D, ng/ml16.2 (11.5 − 22.4)15.3 (11.0 − 20.7)16.2 (11.5 − 22.4)2543 (4.6)Data presented as n (% of either overall, diabetic, or non-diabetic population) for categorical and as mean (standard deviation) for continuous variables regarding demographics, diabetes treatment and risk factors, and as median (Q1-Q3) before transformations (square root for HDL, LDL and triglycerides, cube root for others), winsorizing and imputations for biomarkers.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Some early surveys did not differentiate between type 1 and type 2 diabetes and for this reason they were analyzed jointly (however, 16% of the diabetic participants were receiving insulin treatment at baseline).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM/BiomarCaRE consortium

Study design awaiting verification · Cardiovascular Diabetology · 2021

Original publication title

Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM/BiomarCaRE consortium

Matti A. Vuori; Jaakko Reinikainen; Stefan Söderberg; Ellinor Bergdahl; Pekka Jousilahti; Hugh Tunstall-Pedoe; Tanja Zeller; Dirk Westermann; Susana Sans; Allan Linneberg; Licia Iacoviello; Simona Costanzo; Veikko Salomaa; Stefan Blankenberg; Kari Kuulasmaa; Teemu J. Niiranen

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The findings suggest that the main mediators of heart failure in diabetes are obesity, hyperglycemia, and cardiac strain/volume overload. Conventional cardiovascular risk factors are strongly related to incident heart failure, but these associations are not stronger in diabetic than in non-diabetic individuals. Active measurement of relevant biomarkers could potentially be used to improve prevention and prediction of heart failure in high-risk diabetic patients.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

The risk of heart failure among diabetic individuals is high, even under tight glycemic control. The correlates and mediators of heart failure risk in individuals with diabetes need more elucidation in large population-based cohorts with long follow-up times and a wide panel of biologically relevant biomarkers.

Source: Background

Abstract: What methods does the paper describe?

In a population-based sample of 3834 diabetic and 90,177 non-diabetic individuals, proportional hazards models and mediation analysis were used to assess the relation of conventional heart failure risk factors and biomarkers with incident heart failure.

Source: Methods

Abstract: Results

Over a median follow-up of 13.8 years, a total of 652 (17.0%) and 5524 (6.1%) cases of incident heart failure were observed in participants with and without diabetes, respectively. 51.4% were women and the mean age at baseline was 48.7 (standard deviation [SD] 12.5) years. The multivariable-adjusted hazard ratio (HR) for heart failure among diabetic individuals was 2.70 (95% confidence interval, 2.49 to 2.93) compared to non-diabetic participants. In the multivariable-adjusted Cox models, conventional cardiovascular disease risk factors, such as smoking (diabetes: HR 2.07 [1.59 to 2.69]; non-diabetes: HR 1.85 [1.68 to 2.02]), BMI (diabetes: HR 1.30 [1.18 to 1.42]; non-diabetes: HR 1.40 [1.35 to 1.47]), baseline myocardial infarction (diabetes: HR 2.06 [1.55 to 2.75]; non-diabetes: HR 2.86 [2.50 to 3.28]), and baseline atrial fibrillation (diabetes: HR 1.51 [0.82 to 2.80]; non-diabetes: HR 2.97 [2.21 to 4.00]) had the strongest associations with incident heart failure.

In addition, biomarkers for cardiac strain (represented by nT-proBNP, diabetes: HR 1.26 [1.19 to 1.34]; non-diabetes: HR 1.43 [1.39 to 1.47]), myocardial injury (hs-TnI, diabetes: HR 1.10 [1.04 to 1.16]; non-diabetes: HR 1.13 [1.10 to 1.16]), and inflammation (hs-CRP, diabetes: HR 1.13 [1.03 to 1.24]; non-diabetes: HR 1.29 [1.25 to 1.34]) were also associated with incident heart failure. In general, all these associations were equally strong in non-diabetic and diabetic individuals. However, the strongest mediators of heart failure in diabetes were the direct effect of diabetes status itself (relative effect share 43.1% [33.9 to 52.3] and indirect effects (effect share 56.9% [47.7-66.1]) mediated by obesity (BMI, 13.2% [10.3 to 16.2]), cardiac strain/volume overload (nT-proBNP, 8.4% [-0.7 to 17.4]), and hyperglycemia (glucose, 12.0% [4.2 to 19.9]).

Source: Results

Abstract: Conclusions

The findings suggest that the main mediators of heart failure in diabetes are obesity, hyperglycemia, and cardiac strain/volume overload. Conventional cardiovascular risk factors are strongly related to incident heart failure, but these associations are not stronger in diabetic than in non-diabetic individuals. Active measurement of relevant biomarkers could potentially be used to improve prevention and prediction of heart failure in high-risk diabetic patients.

Source: Conclusions
Authors’ abstract

Background

The risk of heart failure among diabetic individuals is high, even under tight glycemic control. The correlates and mediators of heart failure risk in individuals with diabetes need more elucidation in large population-based cohorts with long follow-up times and a wide panel of biologically relevant biomarkers.

Methods

In a population-based sample of 3834 diabetic and 90,177 non-diabetic individuals, proportional hazards models and mediation analysis were used to assess the relation of conventional heart failure risk factors and biomarkers with incident heart failure.

Results

Over a median follow-up of 13.8 years, a total of 652 (17.0%) and 5524 (6.1%) cases of incident heart failure were observed in participants with and without diabetes, respectively. 51.4% were women and the mean age at baseline was 48.7 (standard deviation [SD] 12.5) years. The multivariable-adjusted hazard ratio (HR) for heart failure among diabetic individuals was 2.70 (95% confidence interval, 2.49 to 2.93) compared to non-diabetic participants. In the multivariable-adjusted Cox models, conventional cardiovascular disease risk factors, such as smoking (diabetes: HR 2.07 [1.59 to 2.69]; non-diabetes: HR 1.85 [1.68 to 2.02]), BMI (diabetes: HR 1.30 [1.18 to 1.42]; non-diabetes: HR 1.40 [1.35 to 1.47]), baseline myocardial infarction (diabetes: HR 2.06 [1.55 to 2.75]; non-diabetes: HR 2.86 [2.50 to 3.28]), and baseline atrial fibrillation (diabetes: HR 1.51 [0.82 to 2.80]; non-diabetes: HR 2.97 [2.21 to 4.00]) had the strongest associations with incident heart failure.

In addition, biomarkers for cardiac strain (represented by nT-proBNP, diabetes: HR 1.26 [1.19 to 1.34]; non-diabetes: HR 1.43 [1.39 to 1.47]), myocardial injury (hs-TnI, diabetes: HR 1.10 [1.04 to 1.16]; non-diabetes: HR 1.13 [1.10 to 1.16]), and inflammation (hs-CRP, diabetes: HR 1.13 [1.03 to 1.24]; non-diabetes: HR 1.29 [1.25 to 1.34]) were also associated with incident heart failure. In general, all these associations were equally strong in non-diabetic and diabetic individuals. However, the strongest mediators of heart failure in diabetes were the direct effect of diabetes status itself (relative effect share 43.1% [33.9 to 52.3] and indirect effects (effect share 56.9% [47.7-66.1]) mediated by obesity (BMI, 13.2% [10.3 to 16.2]), cardiac strain/volume overload (nT-proBNP, 8.4% [-0.7 to 17.4]), and hyperglycemia (glucose, 12.0% [4.2 to 19.9]).

Conclusions

The findings suggest that the main mediators of heart failure in diabetes are obesity, hyperglycemia, and cardiac strain/volume overload. Conventional cardiovascular risk factors are strongly related to incident heart failure, but these associations are not stronger in diabetic than in non-diabetic individuals. Active measurement of relevant biomarkers could potentially be used to improve prevention and prediction of heart failure in high-risk diabetic patients.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12933-021-01378-4.

Publication and source details

Original title: Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM/BiomarCaRE consortium

Matti A. Vuori; Jaakko Reinikainen; Stefan Söderberg; Ellinor Bergdahl; Pekka Jousilahti; Hugh Tunstall-Pedoe; Tanja Zeller; Dirk Westermann; Susana Sans; Allan Linneberg; Licia Iacoviello; Simona Costanzo; Veikko Salomaa; Stefan Blankenberg; Kari Kuulasmaa; Teemu J. Niiranen

Cardiovascular Diabetology · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/501100004037Juho Vainion Säätiöhttp://dx.doi.org/10.13039/501100009420Varsinais-Suomen SairaanhoitopiiriUniversity of Turku Foundationhttp://dx.doi.org/10.13039/501100005633Sydäntutkimussäätiöhttp://dx.doi.org/10.13039/501100004756Emil Aaltosen Säätiöhttp://dx.doi.org/10.13039/501100005878Terveyden Tutkimuksen Toimikunta321351Niiranen Teemu J.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T11:41:00.599069+00:00

DOI: 10.1186/s12933-021-01378-4 · PMC8479921